SCHEMBL2376175

SCHEMBL2376175

c1ccc(Nc2ncnc3sccc23)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
RAB9A P51151 6/20 0.69
EGFR P00533 3/20 0.69
FADS1 O60427 1/20 0.69
NPC1 O15118 4/20 0.67
ALDH1A1 P00352 1/20 0.67
GAA P10253 1/20 0.67
PIP4K2A P48426 4/20 0.63
PIP4K2C Q8TBX8 1/20 0.63
MAPT P10636 2/20 0.59
POLB P06746 1/20 0.59
PIP4K2B P78356 1/20 0.59
KDM4E B2RXH2 1/20 0.59
MAPK1 P28482 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
TNF P01375 1/20 0.58
NOD1 Q9Y239 1/20 0.58
RAF1 P04049 1/20 0.58
PDGFRB P09619 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6923033 0.85 PIP4K2A (0.73) MEN1KMT2ARAB9AEGFRFADS1
SCHEMBL16363310 0.84 KMT2A (0.73) MEN1KMT2ARAB9AEGFRFADS1
SCHEMBL4738626 0.82 FADS1 (1.00) MEN1KMT2ARAB9AEGFRFADS1
SCHEMBL810888 0.82 EGFR (1.00) MEN1KMT2ARAB9AEGFRFADS1
Hydrochloric Acid SCHEMBL6836391 0.81 EGFR (0.97) MEN1KMT2ARAB9AEGFRFADS1
SCHEMBL9431935 0.78 KMT2A (0.54) MEN1KMT2ARAB9AEGFRFADS1
SCHEMBL3799139 0.78 MEN1 (0.54) MEN1KMT2ARAB9AEGFRFADS1
SCHEMBL30827872 0.78 PIP4K2A (0.64) MEN1KMT2ARAB9AEGFRFADS1
SCHEMBL3395499 0.77 RAB9A (0.70) MEN1KMT2ARAB9AEGFRNPC1
SCHEMBL5315096 0.76 RAB9A (0.79) MEN1KMT2ARAB9AEGFRFADS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249155-B2 Thieno [2, 3-D] pyrimidine derivatives and their use to treat arrhythmia XENTION LIMITED (GB) 2016-02-02 US disclosed
EP-2694518-B1 THIENO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE TO TREAT ARRHYTHMIA XENTION LTD (GB) 2015-10-07 EP disclosed
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 MEN1 265/4885KMT2A 1857/4885RAB9A 1622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.